期刊
INTERNATIONAL JOURNAL OF CANCER
卷 135, 期 8, 页码 1961-1969出版社
WILEY
DOI: 10.1002/ijc.28829
关键词
apatinib; VEGFR2; metastatic breast cancer; triple negative
类别
资金
- Shanghai Municipal Health Bureau Scientific Project [201049]
- HengRui Pharmaceuticals Inc.
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II study aims to evaluate the optimum dose level for the efficacy and safety of apatinib monotherapy in heavily pretreated patients with metastatic triple negative breast cancer (mTNBC) in China. Phase ha was first performed among 25 patients previously treated with anthracycline and/or taxane. All patients received apatinib 750 mg/day p.o. in a 4-week cycle. Subsequently, a phase Ilb study of 59 patients was activated, with the endpoint progression-free survival (PFS). The dosage of drug for the Phase Ilb was determined according to safety, tolerability and efficacy from the phase Ila study. As a result of toxicity associated with the 750 mg dose in phase Ila, the recommended initial dose of apatinib in the phase Ilb was 500 mg/day. In phase Ilb, grade 3/4 hematologic toxicities were thrombocytopenia (13.6%), leukopenia (6.8%), neutropenia (3.4%) and anemia (1.7%). The most frequent grade 3/4 nonhematologic toxicities were hand foot syndrome, proteinuria, hypertension, and increased ALT. In the 56 evaluable patients, overall response rate and clinical benefit rate (CBR) were 10.7 and 25.0%, respectively. Median PFS and overall survival were 3.3 (95% Cl 1.7-5.0) and 10.6 (95% CI 5.6-15.7) months, respectively. Our results indicate that apatinib dose of 500 mg rather than 750 mg is the recommended starting dose for the heavily pretreated mTNBC patients with measurable rate of partial response and PFS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据